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Article Information  ABSTRACT 
Received: 21st November 2015  Tuberculosis (TB) is a major global health threat. The emergence of human immunodeficiency 
virus (HIV) and also multi drug resistant (MDR) and extremely drug resistant (XDR)-TB poses 
a vital challenge to the control of the disease. For the last 50 years, no new anti-TB drug has 
been discovered. This literature review provides a brief discussion of existing drugs and 
emerging drug targets, and also of the advantages of incorporating modern drug delivery 
systems and immune modulators in order to improve the existing treatment regimen in terms of 
better efficacy, reduced drug administration frequency, shortened period of treatment and 
reduced drug related toxicity. The investigation for a new drug target is essential to continue the 
battle against MDR and XDR-TB. However, owing to the enormous cost and time involved in 
new drug development, improvement of the existing treatment regimen is seen to be a valid 
alternative.   
Revised: 05th December 2015 
Accepted: 19th December 2015 
   
Keywords 
Tuberculosis, multi drug resistant, 
extremely drug resistant, immune 
modulators 
 
 
INTRODUCTION 
Tuberculosis (TB) is the leading cause of death by a single 
treatable infectious disease; killing approximately 5,000 people 
per day throughout the world as the World Health Organization 
(WHO) reported 1.8 million deaths due to TB in 2008 [1]. The 
bacteria involved is a member of Mycobacterium  family  
which has  over  60  species  with only a few like  
Mycobacterium  tuberculosis  (Mtb), Mycobacterium leprae, 
Mycobacterium africanum and  Mycobacterium  avium that 
cause human diseases.   Mtb   can  exist  in  the  human  body  
for  a  long  time  without  showing  any  clinical  symptoms;  
this  phase  is  called  the  latent  stage. Once the host’s immune 
system becomes weakened, either because of age or concurrent 
disease, the bacteria attain virulent or turn to the active form. 
Human immunodeficiency virus (HIV) infection weakens the 
immune system, thereby facilitating the infection or 
reactivation of the TB bacteria. Co-infection with TB and HIV 
synergistically influence each other’s progress, rendering the 
host vulnerable to death.[1-2] TB is highly contagious during the 
active stage of the disease and it can be caused by inhaling as 
low as 10 bacteria. [3] After inhaling, these bacteria are mainly 
captured by the alveolar macrophages, but they can evade the 
host immune system and remain in the dormant stage for a long 
time and can then be reactivated to virulent form under the 
immune compromised conditions of the host. This is possible 
because Mtb can persist in slow growing as well as in fast 
growing stages and this unique characteristic of Mtb makes 
treatment challenging. Almost all the antibiotics work when the 
bacteria are actively dividing. In the intensive phase of TB 
treatment, the antibiotics mainly kill the rapidly growing 
bacteria, causing rapid sputum conversion, and eradicate the 
clinical symptoms. In order to kill the persistent or slow 
growing strains of Mtb, the continuation phase of the treatment 
is essential. TB can be treated effectively by using the first line 
drugs (FLD) which are isoniazid (INH), rifampin (RIF), 
pyrazinamide (PZA) and ethambutol (ETH). But this first line 
therapy often fails to cure TB for several reasons. Firstly, the 
treatment regimen is long, consisting of an initial 2 months of 
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intensive phase treatment with all four drugs, followed by the 
continuation phase for 4 months with INH and RIF. The 
lengthy therapy period with multi drug treatment results in a 
lack of compliance causing the treatment failure. This results in 
relapse and pread of the disease and also contributes to the 
emergence of drug resistant bacteria. Secondly, these first line 
anti-TB drugs have toxic effects including hepatotoxicity, 
neurotoxicity and strong drug-drug interaction, especially when 
administered with anti retroviral drugs. Thirdly, emergence of 
multi drug resistant (MDR) and extremely drug resistant 
(XDR) TB further complicates the situation. The patients with 
MDR and XDR have to be treated with second line drugs 
which are more toxic and expensive (50-200 times costlier than 
FLD) [4], with longer treatment schedules of up to 2 years. A 
cost analysis study conducted by the Colorado physicians, the 
total treatment cost for treating the drug susceptible TB is 
found to be approximately US $1,206 per patient.[5] The cost 
includes those of drugs and their administration, tests to 
evaluate treatment progress and also tests to assess 
hepatotoxicity; however, the figure does not include the 
patient’s time cost. Another study conducted in Philippines, 
found the total cost for treating MDR-TB was around US 
$3,355 per patient.[6] Finally, after the initial intensive phase of 
the treatment, when the disease symptoms subside, many 
patients stop taking medication mainly because of high pill 
count and associated toxic effects. The discontinuation of 
therapy facilitates the emergence of MDR and XDR strains. 
The emergence of MDR and XDR-TB underscore the necessity 
of a new line of tuberculosis drugs. A study conducted in South 
Africa reported an average 16 day survival, between diagnosis 
and death among the patients co-infected with XDR-TB and 
HIV. [7] The discovery of the complete genome sequence of TB 
bacteria helped to identify several important drug targets [9] and 
fortunately, many new drugs are in the clinical trial stage. 
Currently, the approximate cost of developing a new drug is 
$800 million to $1.7 billion [9] with considerable involvement 
of time. This fact highlights the importance of improving the 
existing treatment options - in terms of shortening the treatment 
period, reducing the frequency of drug administration and 
associated toxicity, and also targeting the dormant population 
of the bacteria - in order to control the drug susceptible strain 
and thereby minimize the emergence of MDR and XDR-TB. 
The initial part of this review focuses on the new and emerging 
drugs and their targets. In the latter part the focus shifts towards 
the two main ways to improve the existing treatment regimen 
exploiting modern drug delivery systems and incorporating 
immune modulators within the formulation. This cocktail 
formulation has the potential to solve many of the hurdles 
present in the existing TB therapy.  
 
EXISTING AND EMERGING DRUGS 
First line drugs 
There has been a drought of new anti-TB drugs for more than 
50 years. The drugs isoniazid (INH), rifampin (RIF), 
pyrazinamide (PZA) and ethambutol (ETH) are collectively 
called the first line of drugs (FLD). The FLDs work fine for 
drug susceptible strains of the bacteria, in fact until now INH 
and RIF are the two most effective drugs against Mtb. Among 
the available FLDs, only pyrazinamide can work on the 
persistant population of the bacteria [10] but none can kill the 
dormant population of the bacteria which cause latent disease 
and if left untreated can cause relapse of the disease under 
immune compromised condition. In many bacterial infections 
the small residual bacteria, left after antibiotic treatment, can 
beeffectively killed by the host immune system. But that does 
not happen in TB [11] as the host is already in immune 
compromised condition and moreover the TB bacteria 
constantly manipulatearound the host’s already weakened 
immune system. So it takes usually 6 months to treat the 
disease if the bacteria are drug susceptible. The brief summary 
of individual FLDs, regarding their mode of action and activity, 
is shown in Table.1.   
 
New and emerging drugs 
Fluoroquinolones 
This class of drugs consists of ofloxacin, ciprofloxacin, 
gatifloxacin, moxifloxacin and many others. Though some of 
the drugs were discovered earlier but their anti TB activities 
have been reported recently. This group of drugs has good 
pharmacokinetic behaviour which may help to reduce the 
frequency of drug administration; they also can penetrate the 
tissues very well, including  macrophages [12, 13]the primary 
docking site for the TB bacteria. Their toxicity levels were also 
less adverse when administered alone. [12] However, 
moxifloxacin, when administered along with RIF and PYZ, 
showed considerable toxic effects as it is well known that the 
latter two show fatal hepatotoxicity when used in 
combination.[14] The combination regimen of these three 
showed better performance than INH, RIF and PYZ in the 
mouse model. [15] The moxifloxacin is in phase 3 clinical trials 
Sarangi et. al
 
An overview of tuberculosis chemotherapy – a literature review 
 
 
Journal of Applied Pharmaceutical Research  January  – March 2016  Volume 4 Issue 1  22 
undertaken by the TB Alliance Group. Many of the 
fluoroquinolones are used as second line drugs in TB patients 
but fluoroquinoloneresistant bacteria are emerging at a faster 
rate. In fact, in the Philippines, 51% of the MDR-TB cases 
were found to be resistant to both ciprofloxacin & ofloxacin[16] 
 
Table 1. The Summery of Different First Line Drugs of TB 
Drug  Discovered                       Mechanism 
of action  
Active against 
Isoniazid 
(INH) 
1912, anti-
TB reported 
on 1951 
Inhibiting the 
cell wall 
synthesis. 
Fast growing 
population of 
the bacteria.  
Pyrazinamide 
(PZA) 
1952 
Inhibiting and 
depleting the 
membrane 
energy. 
Bacteria with 
low metabolic 
activity & can 
survive in 
acidic pH 
Rifampicin 
(RIF) 
1959 
Inhibiting the 
nucleic acid  
synthesis. 
Population with 
spurts of  
metabolism: 
dormant with  
occasional 
short, active  
period of 
metabolism or 
growth 
Ethambutol 
(ETH) 
1961 
Inhibiting the 
cell wall  
synthesis. 
Fast growing 
population &  
mainly used to 
minimize INH  
resistance. 
 
Rifamycin Derivatives:  
The easy way to determine a new compound having anti-TB 
activity is to try different derivatives of the existing FLDs with 
better pharmacokinetic behaviour, less toxicity and relatively 
new so that no resistant strain has evolved against it. One such 
derivative is rifamycin; this class of drugs contain rifabutin, 
ifalazil, rifapentine and many others. These compounds are a 
modified form of rifampicin (RIF). They are usually more 
active than the parent compound RIF. Rifabutin is 4-8 times 
more active than RIF against Mtb and has a longer half-life and 
good tissue penetration properties. [17] Another major advantage 
of rifabutin over RIF is its relatively low level of drug 
interaction. The Center for Disease Control and Prevention 
(CDC) in the USA recommends rifabutin instead of RIF for 
simultaneous treatment of TB and HIV because of its better 
compatibility with other antiretroviral drug regimens than RIF 
[18, 19] Rifalazil is particularly more potent against TB bacteria.  
In vitro activity of this drug is 100 times higher than RIF and 
also shows better in vivo activity in the mouse model. Better 
efficacy in humans has been reported for once weekly 
administration of it along with daily INH, compared to daily 
administration of both RIF and INH without any significant 
adverse toxicity. [20] 
 
Oxazolidinones:  
This group of compounds has broad spectrum antimicrobial 
activity and some of them are available in the market. These 
drugs exhibit good efficacy against Mtb in the mouse model. 
They work by inhibiting early protein synthesis in the bacteria, 
and the rate of emergence of resistant strain is usually slow[21, 
22]. The second generation of oxazolidinones has less toxicity 
than the first generation, with similar anti-microbial activity. 
Linezolid and PNU-100480 both have shown good efficacy in 
the murine model[23]. Linezolid sometimes has been used 
outside its label claim as an anti-TB drug in MDR and XDR-
TB[23] 
 
Nitroimidazoles:  
The most effective drug in this group is nitroimidazopyran PA-
824. It can simultaneously inhibit protein and lipid synthesis of 
the mycobacteria and exhibit bactericidal activity against both 
replicating and dormant populations of the bacteria. [24] This 
drug has the potential to treatboth active and latent TB and it is 
currently in Phase II trial taken by the TB Alliance. [15] Like all 
nitroimidazoles, it is also utagenic and carcinogenic but to a 
lesser extent than other parent compounds. This can be a major 
concern towards its development as a good anti-TB drug. [25] 
 
Azole Drugs:  
The drugs like miconazole and clotrimizole are active against 
Mtb. [26]They target the cytochrome P450 homologs in the 
bacteria. The subsequent crystallisation of Mtb cytochrome 
P450 enzyme system initiated studies to evaluate new drug. [27] 
 
Diarylquinoline:  
TMC 207 is the lead compound of this series. It is effective 
against all the pathogenic strains of mycobacteria which cause 
TB. In addition it is equally effective in drug susceptible as 
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well as drug resistant strains of the bacteria. That is why TMC 
207 is the first ever TB drug that is in trial in both forms of TB 
(drug susceptible and resistant) by TB Alliance. [28] Human 
studies with this drug have showed good efficacy in MDR-TB, 
with acceptable toxic effect. [29] This drug targets a novel ATP 
synthase of the bacteria.[30, 31] 
 
Phenothiazines:  
Phenothiazines like chlorpromazine and thioridazine are 
antipsychotic drugs with considerable anti-TB activity. [32, 34] In 
vitro, they can inhibit both drug susceptible as well as drug 
resistant bacteria. Their anti-TB activity is partly due to their 
relative concentration in macrophages where there is a 
maximum concentration of the TB bacteria.[33, 35, 36] 
 
Peptide deformylase inhibitors:  
Peptide deformylase inhibitors is a metalloprotease enzyme 
essential for maturation of nascent polypeptides in bacteria but 
not essential for humans. [37] This is a relatively new drug target 
having anti-TB activity and has the potential of a future drug 
target. [38] In the BCG strain of TB, this gene is absolutely vital 
for the bacteria’s survival [39] but unfortunately this drug target 
has little effect on the slow growing TB bacteria. [40] 
 
Some new emerging drug targets:  
Ever since the discovery of the complete genome sequence [8] 
of a virulent strain of TB bacteria, lots of new drug targets have 
been identified, and some of them are showing promise in 
animal models. The evaluation of new drug targets is essential 
to carry on the constant battle against the drug resistant strains 
of TB.  Some of the recent and promising drug targets are 
discussed below: The cell wall of Mtb is very important for the 
bacteria’s survival within constrained conditions like the inside 
of human macrophages. The biosynthesis of the cell wall 
components involves many important stages and different 
enzymes [40, 41] and these enzymes are attractive drug targets. 
Another advantage of targeting this system is its absence in the 
mammalian system. Two of the important first line drugs, 
isoniazid and ethambutol, work by inhibiting the bacterial cell 
wall synthesis. The search is ongoing for new targets. Recently, 
the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway was 
found to be an attractive one [42] and the drug fosmidomycin 
inhibits this pathway. This pathway has the potential for a good 
drug target since the end product of this pathway leads to the 
formation of isoprenoids, responsible for the synthesis of 
several cell wall components.[43-45]Mtb has a large repertoire of 
lipophilic molecules which is quite uncommon in the bacterial 
population. For example, E.coli has around 50 lipid 
metabolizing enzymes and the corresponding number for Mtb 
is roughly 250 which include many of the fat metabolizing 
enzymes found in plant and mammalian systems.[40] This 
underscores the importance of this group of compounds in TB 
bacteria. Isocitratelyase (ICL) is an important enzyme in this 
category and also an important drug target. ICL is involved in 
energy production via the metabolism of acetyl-CoA and 
propionyl-CoA. The inactivation of Icl gene leads to 
attenuation of both the persistent and virulent strains of TB 
bacteria.[46] A recent study revealed that the bacteria even had a 
salvage pathway in the presence of ICL inhibitor, provided they 
can scavenge vitamin B12 from the host.[47] These findings 
highlight the prospect of a good anti TB drug capable of 
blocking the main and salvage pathways, simultaneously. 
Amino acid biosynthesis is another important target for 
developing anti-TB drugs. The shikimate pathway is in 
particular very important. It is involved in the synthesis of the 
aromatic amino acids in the algae, fungi, bacteria and higher 
plants but it is bsent in the mammalian system. This feature 
makes the pathway an attractive target for developing anti TB 
drugs with minimum cross reactivity. [48] In fact, the inhibitor 
of this pathway acts as a promising herbicide and research is 
ongoing for developing an anti-mycobacterial drug by 
exploiting the enzymes involved in this pathway. The 
biosynthesis of non-aromatic amino acids is also an emerging 
drug target. The impact of amino acids like lysine, proline, 
tryptophan and leucine was evident from the fact that the Mtb 
strain, knocked out of the genes required for the biosynthesis of 
above mentioned amino acids, showed less virulence even in 
the severe combined immunodeficiency mouse model.[49, 50] 
The PhoPR is a two component signal transduction system 
found in mycobacteria and this system is vital for acterial 
virulence. The PhoP mutant strain of Mtb showed less 
virulence. [51] This mutant strain of Mtb also showed lesser 
secretion of ESAT-6 and CFP-10, two major immunodominant 
protein antigens present inpathogenic TB bacteria.[52] The 
suitable inhibitor for this system can serve as an important drug 
for TB treatment. The stringent response enzyme is essential 
for bacteria’s long time survival within the host; therefore, 
targeting the enzyme can subsequently reduce the treatment 
period. [53] Another important set of emerging drug targets is 
the components of the siderophore biosynthesis of Mtb[54]. 
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Upon infection, as a part of the defence mechanism, the host 
has several mechanisms to withdraw or control the free 
extracellular as well as intracellular iron concentration. [55] The 
siderophores are high affinity iron chelating compounds 
present in bacteria that help them to acquire iron from the iron 
deficit environment of the host. The carboxymycobactins and 
mycobactins are two types of siderophore present in Mtb. An 
antibiotic named 5’-O-[N- (salicyl)sulfamoyl] adenosine was 
reported to block the biosynthesis of both and hence the 
replication of Mtb,  in vitro, under iron constrained conditions. 
[56] 
 
Role of Nanoparticles in Anti-TB Drug Delivery:  
A holistic review outlined the difficulties in assessing the 
treatment adherence towards anti TB therapy. [57] The patients’ 
compliance to the existing multi drug regimen for TB treatment 
is very poor and that leads to further complication of the 
disease condition. The poor compliance is caused by the 
prolonged treatment period and high daily pill count which also 
enhance the drug related toxicity. One of the major milestones 
to achieve good compliance rate is either to reduce the total 
period of drug treatment or to cut down the daily pill count. 
This can be achieved by incorporating sophisticated 
formulation echniques. Encapsulating the anti TB drugs within 
a micro or nanoparticle can greatly enhance the bioavailability 
of the drugs and thereby reduce the frequency of drug 
administration to, say, once weekly compared to the existing 
daily intake. This type of encapsulated formulation acts as a 
drug reservoir and slowly releases the drug over a prolonged 
period of time. Synthetic as well as natural materials are used 
to design the particles. The synthetic components include poly 
(DL-lactide-co-glycolide) (PLG), poly lactic acid, poly glycolic 
acid etc and the natural components include liposome, alginic 
acid, chitosan, gelatin etc. The selection of the constituent 
material and the associated excipients are dependent upon the 
route of delivery, the required rate of drug release and the 
properties of the drugs to be encapsulated. [58] The advantage of 
all the above mentioned components is their biodegradability 
so they are easily eliminated from the body.  
 
Synthetic nanoparticles material:  
Many groups of scientists are working on the advantage of 
incorporating anti TB drugs exploiting modern drug delivery 
systems. In a study conducted by Pandey  et.al., three first line 
anti TB drugs, namely, INH, RIF and PYZ, were encapsulated 
in PLG nanoparticle (PLG-NP) and administered orally (once 
every 10 days) in Mtb infected mice. The pharmacokinetic 
parameters were compared with that of the daily free drug 
administration. In the group treated with PLG-NP, the 
minimum inhibitory concentration was maintained for 6-9 days 
in plasma and 9 days in organs (liver, lungs and spleen) but in 
the free drugs group, the same level was maintained for 12-24 
hours only. No bacterial load was found in the PLG-NP treated 
group compared to the untreated mice. [59] The same 
investigators found similar results when the study was 
conducted in the guinea pig model [60] and in the mouse model 
using nhalable PLG-NP. [61]None of the studies found any sign 
of hepatotoxicity.   
 
Natural nanoparticles materials:  
In another study, INH and RIF were encapsulated in liposomes 
tagged with o-stearyl amylopectin and administered 
intravenously in infected mice. The o-stearyl amylopectin 
tagging facilitates the targeting of the drug towards the lung 
tissue. [62] The clearing of bacterial load was achieved within 6 
weeks of drug administration (once weekly) and using 1/3rdof 
their corresponding therapeutic dose with no sign of 
hepatotoxicity. [63] Similar kind of prolonged drug activity, with 
lower frequency of dose and lower amount of drug 
administration, was observed in the drugs encapsulated in 
alginic acid-chitosan nanoparticle. [64] The major advantages of 
these natural materials over the synthetic polymers were 
discussed in a review by Pandey et.al. [58] Briefly, the non-
requirement of any expensive organic solvents during the 
encapsulation step, higher aqueous matrix and high gel porosity 
are some of the advantages, and moreover some of the 
components are already approved for clinical use in different 
formulations [60]The current status of the nanoparticle research 
with TB drugs is discussed in details in a recently published 
review. [65] 
 
Immune-Modulator In TB Therapy:  
In many other bacterial infections, the time required to treat the 
disease is comparably less because nce the drug initiates the 
killing of the majority of the bacilli, the host immune system 
can take care of the residual bacilli. But this does not happen in 
TB, mainly because TB bacteria impair the host immune 
system. [66] There are some well-established TB antigens which 
can manipulate the host immune system [67, 68] and thereby 
render it incapable of fighting off the residual bacteria on its 
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own. In order to counter balance this scenario, the 
incorporation of immune-modulators in the treatment regimen 
for TB seems to be a logical option.  
 
The cytokines as modulators:  
The cytokines are very powerful immunomodulators and 
different studies have shown their involvement during 
mycobacterial infections. Like all other bacterial infections, 
Th1 response, the intracellular cell mediated immunity, is vital 
for protection against TB infection. So the cytokines that 
promote the Th1 response should be able to provide better 
protection. IL-12 plays an important role towards the 
enhancement of Th1 response. During TB infection, IL-12 
promotes the secretion of interferon-gamma (IFN-γ), tumour 
necrosis factor α (TNF-α) and granulocyte-macrophage colony-
stimulating factor, all of them polarise the immune response 
towards Th1, via the activation of natural killer (NK) cells. [69] 
The exogenous administration of IL-12 in mice showed 
enhanced resistance towards the intravenously infected Mtb 
bacteria. [70] The IL-12 knockout mice showed higher 
susceptibility towards the mycobacterial infection. [70] The 
defect or deletion in the IL-12 receptor gene leads enhanced 
susceptibility not only towards the pathogenic mycobacteria 
but also towards the nonpathogenic mycobacteria including 
bacillus Calmette-Guérin (BCG) vaccine strain. [71, 72] This 
condition is referred as Mendelian Susceptibility to 
Mycobacterial Disease, a disease caused by gene defect. The 
ncorporation of IL-12 microsphere in the TB subunit vaccine 
showed enhanced immunity and protection. [73] Enhanced 
treatment efficacy was obtained by concomitant use of rifabutin 
and clarithromycin along with IL-12 in severe combined 
immunodeficiency as well as in wild type mice in 
Mycobacterium avium complex (MAC) model. [74] These 
findings underscore the crucial role of IL-12 during TB 
infection. However, tissue toxicity and induction of 
autoimmunity are two major concerns that limit the therapeutic 
use of IL-12. The researcher found that combined gene therapy 
with IL-12 and granulocyte-macrophage colony-stimulating 
factor in the mouse hepatocellular carcinoma model resulted in 
increased efficacy with decreased toxicity. [75] IFN-γ is another 
crucial immunomodulator that plays a vital role during TB 
infection, although there are contradictory findings in literature 
regarding the role of IFN-γ in TB. Some older studies reported 
that IFN-γ pre-treated human macrophages were more 
susceptible to TB-bacterial growth. [76, 77] However, the 
researchers also found that IFN-γ administration in aerosol 
form resulted in rapid recovery in MDR-TB patients. [78] The 
administration of IFN-γ, along with anti-MAC drugs, showed 
better bacterial clearance profile in the MAC and AIDS co-
infected patients [79]. The difference in TB susceptibility in 
different populations had also been linked to polymorphism in 
the IFN-γ gene. [80-82] TNF-α, another crucial proinflammatory 
cytokine, activates macrophages to liberate nitric oxide 
synthase-2 which is responsible for killing the intracellular 
Mtb. [83, 84] The mice deficient of TNF-α secretion and 
corresponding receptor showed higher susceptibility towards 
TB. [85, 86] In humans, drug treatment with infleximab (a 
monoclonal antibody that inhibits TNF-α) increases TB 
susceptibility. [87] IL-10 is an important immunosuppressive 
cytokine that can polarise the immune response towards T-
helper cells of type 2 (Th2). The mouse macrophages infected 
with Mtb showed increased production of IL-10 which 
suppresses the production of Th1 promoting cytokine, IL-12. 
[88] In order to kill the bacteria residing within the cell, the Th1 
cytokines which have intracellular access are absolutely 
essential. Many TB antigens have the property to switch the 
immune response towards the Th2 [70] and thereby able to 
survive within the cell. This response can be reversed by 
blocking the IL-10 receptor. The incorporation of anti-IL-10 
receptor antibody in the multi-drug regimen of anti MAC 
treatment showed enhanced efficacy in the mouse model. [89]A 
similar kind of enhanced Th1 response was also observed in the 
in vitro study with human peripheral blood mononuclear cell 
isolated from hepatitis C virus infected patients. [90] 
 
Non-cytokine modulators:  
The incorporation of these immune modulating cytokines in TB 
treatment may sound promising, but these cytokines 
occasionally lead to serious side effects and moreover, they are 
very expensive. Owing to the fact that tuberculosis is mainly 
concentrated in the resource constrained countries, the 
feasibility of incorporating these expensive cytokines in the 
treatment regimen is a debatable issue. This problem can be 
partially overcome by using simple chemical agents capable of 
doing the immunomodulation task like ATP and its analogs, 
picolinic acid, imidazoquinoline, calcitriol, the Chinese 
traditional medicine Mao-Bushi-Saishin-To, heat killed 
Mycobacterium vaccae etc. [69] The vitamin D and glutathione 
are two simple compounds also capable of doing so. The 
benefit of vitamin D in TB patients is a long known fact. In the 
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pre-antibiotic era, the TB patients were encouraged to have sun 
exposure and cod liver oil, both of which increase the vitamin 
D synthesis in the body. [91-93]Some scientists traced the anti-TB 
property of vitamin D with toll like receptor signaling. [94] The 
different polymorphism in vitamin D receptor gene showed 
varied susceptibility towards TB. [92] Some studies also pointed 
out that vitamin D enhanced the production of cathelicidin, an 
antimicrobial polypeptide, which kills the bacteria. [92, 95] 
Glutathione (GSH), a tri-peptide synthesised in the human 
body, is capable of protecting the cell against oxidative damage 
by scavenging the reactive free radicals, reactive oxygen 
intermediates and various other oxidizing agents.  In addition, 
GSH level in antigen presenting cells dictates the cytokine 
profile, either Th1 or Th2. [96]The lack of GSH promotes the 
Th2 cytokine secretion. [98] A recent study found the lower 
level of GSH in patients with active pulmonary tuberculosis 
compared to the healthy human. [97] Nitric oxide (NO) is an 
important killing agent for Mtb but NO has short biological 
activity and is rapidly converted to nitrate and nitrite, neither of 
which has the mycobacteriocidal activity. GSH acts as a carrier 
for NO by forming GSNO which subsequently delivers the 
effector NO to inhibit the bacterial growth. [98] The role of GSH 
in the macrophage infected with Mtb was studied in vitro and 
the addition of Buthioninesulphoximine which specifically 
inhibits GSH synthesis, resulted in enhanced growth of 
bacteria. [99] On the other hand, the incorporation of N-acetyl 
cysteine, a glutathione precursor, in the Mtb infected human 
macrophages was found to inhibit significant bacterial growth. 
[100] These findings suggest the favourable role of GSH in the 
treatment of TB, although further studies are required to 
establish the beneficial effect of GSH by co-administering it 
along with anti-TB drugs.   
 
The Proposed Cocktail Formulation:  
Almost all first line anti-TB drugs have limited aqueous 
solubility, stability and bioavailability when administered in 
oral solid or liquid dosage form. [101]To overcome this problem, 
the existing oral formulations need to be administered in higher 
concentration so that the minimum inhibitory concentration in 
serum can be achieved to kill the bug. This higher drug content 
in turn worsens the related drug toxicity.  This problem can be 
overcome by encapsulating the drugs along with the immune 
modulators in nanoparticles. Depending upon the size of these 
particles and the route of administration, they can be 
phagocytosed by specific organelle. The particles in the size 
range of 1-10 µm are found to be predominantly taken up by 
macrophages [102], the primary pool of TB bacteria in human 
host. The incorporation of the immune modulator can enhance 
the effectivity of the drug treatment. The encapsulated 
formulation will act as a drug reservoir by controlling the 
release of the drug which can be further controlled by the 
formulation technique. This kind of formulation has the 
potential to enhance the therapeutic efficacy of the existing TB 
therapy. This type of low dose formulation may restart the 
research for some good anti TB drug candidates whose trials 
were abandoned because of the toxicity at the higher dose.  
The specific targeting can be further facilitated by surface 
decorating these particles with antibody against the specific 
surface markers present in macrophages. In human 
macrophages, the primary receptors for Mtb are the 
complement receptor and the mannose receptor. [103] In addition 
to these receptors, several other surface markers for alveolar 
macrophages have been identified from patients with interstitial 
lung disease. The specific monoclonal antibodies against some 
of those markers can be used to decorate the surface of thedrug 
bearing nanoparticles to facilitate its specific uptake by the 
alveolar macrophages. The specific targeting can enhance the 
maximum utilization of the total incorporated drug and 
therefore require less amount of drug to maintain the minimum 
inhibitory concentration. The less amount of drug incorporation 
and less systemic exposure of the drug will minimize the drug 
related toxicity compared to the existing oral formulations. 
This type of formulation has been tried in the tumour treatment 
[104] but never attempted in the treatment for TB.  
 
Expert Opinion  
In recent years, quite a number of compounds are in different 
stages of clinical trials. This was possible due to the 
harmonized efforts from various Working Groups under the 
STOP TB partnership along with public-private partnerships, 
and contributions from industry and academic researchers. 
[105]The new compounds will be tested in combination with the 
established anti TB drugs to minimise the chance of developing 
drug resistance. [105] 
The continuous research in this field will keep on adding more 
suitable drug candidates into the existing TB drug pipeline. The 
future looks promising in terms of evolving a new TB drug. To 
ensure this progress, continuous efforts and funding are vital 
together with adequate time.  Encapsulated nanoparticles which 
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are surface decorated with different monoclonal antibodies 
(A1, A2 and A3)  
 
A multifaceted approach is required to design a new and 
effective treatment regimen for TB. The new regimen should 
be able to address the followings:  
 Maintain the required concentration of drugs  in vivo 
for a comparatively long time thereby able to reduce 
the frequency of pill administration.  
 Maintain the correct amount of drug concentration at 
the exact target (alveolar macrophages) thereby 
reducing the systemic toxicity.  
 Target the actively dividing as well as dormant 
populations of the bacteria – thereby reducing the time 
required for the treatment.  
 Convenient in terms of administration, schedule, 
length and price – thereby enhancing the patient’s 
compliance.  
Modification of the existing treatment regimen might be useful 
to restrict the current spread of the disease. In this respect, 
incorporation of nanoparticles and immunoadjunctive agents, 
separately or in combination, look promising. There needs to 
be more studies done in order to standardize their efficacy and 
minimize toxicity when co-administered with anti TB drugs 
and also the price of the final ormulation should be user 
friendly.   
 
CONCLUSION  
The chemotherapy of TB will almost always involve a cocktail 
of drugs because of the unique nature of the bacteria. It is 
difficult to design a single drug that can simultaneously kill the 
actively replicating, semi-dormant and dormant populations of 
the bacteria. Among the existing first line drugs, only 
pyrazinamide can effectively kill the slow growing population 
of the bacteria with minimum bactericidal effect on the fast 
growing population. The existing first line of treatment is the 
best available option for treating TB. The designing of new 
treatment regimens is very crucial to control the current spread 
of the TB which is the leading cause of death by a single, 
treatable, infectious disease. [106]There are some challenges 
towards the development of a new treatment regimen for TB. 
Firstly, the unavailability of a suitable animal model that can 
mimic the human disease profile. The mouse model is used 
widely. In most of the studies, the disease is artificially induced 
by using high dose of bacilli by different routes of inoculation. 
The reactivation of TB, the major mode of TB infection in 
human, cannot be mimicked in the mouse model. Moreover, 
there is differential opinion regarding the nitric oxide killing 
mechanism in murine and human macrophages. [107, 108] The 
mice also do not form caseous granuloma, the hallmark of 
human TB infection. Secondly, there is no suitable model that 
can mimic the latent stage of the Mtb. Though various models 
have been tried, like the Wayne model and starvation model 
etc, but none can exactly reflect the scenario observed in the 
latent stage of the disease in humans. In fact, the survival 
mechanism of bacteria in latent stage is not well understood. 
Thirdly, according to a recent study, it takes around $800 
million to $1.7 billion to develop a drug from scratch and to 
bring it to the pharmacy shelf, with considerable involvement 
of time. [10] Moreover, the stringent regulation criteria also 
deter the pharmacy companies from developing any new 
drug[109]. Since TB is a problem mainly for resource 
constrained countries, initially there was less interest by the 
companies to invest in the development of new drugs. But 
because of the steadily deteriorating condition of TB, many 
non-profit organisations came forward in recent years and that 
invigorated TB research. Finally, it is difficult to assess the 
efficacy of a new drug when it is administered along with 
numerous other anti-TB drugs. Annually US$16 billion is 
required to combat TB throughout the globe. [108]  Thus, if 
implementing the particle encapsulation with/without 
immunmodulators, as discussed before, can improve the 
existing treatment regimen then this option may be worthwhile 
to investigate. Moreover, better compliance with the treatment 
can reduce the chance of bacterial evolution towards the drug 
resistant strain by eradicating the bacteria at early stage. The 
discovery of a new chemotherapy regimen for TB, either by 
introducing novel drugs or by modifying the existing ones, 
having the criteria discussed in this review, can revolutionize 
the entire global scenario of the disease.   
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